Benefits of Venetoclax endure years after blood cancer clinical trial
A study which tracked the long-term outcomes of blood cancer patients involved in the MURANO…
Browsing: venetoclax
Combination therapy improves survival outcomes for patients with acute myeloid leukaemia
A combination regimen of venetoclax and azacitidine was safe and improved overall survival (OS) over…
ASCO 2020: Combination therapy well-tolerated and highly effective for patients with IDH1-mutated AML
A combination therapy of ivosenidib (IVO) plus venetoclax (VEN) with or without azacitidine (AZA) was…
Killing ‘sleeper cells’ may enhance breast cancer therapy
The anti-cancer medicine venetoclax could improve the current therapy for estrogen receptor-positive (ER+) breast cancer…
Early data for new drug combination to treat neuroblastoma
Neuroblastoma is the most common cancer outside of the brain in infants and young children…
Prime Minister’s science prizes awarded for algebra expertise, anti-cancer research and excellence in science teaching
Michael Hopkin, The Conversation and Noor Gillani, The Conversation The 2019 Prime Minister’s Prize for…
EHA 2019: Introduction of a new fixed-duration targeted therapy with venetoclax plus obinutuzumab in previously untreated patients with chronic lymphocytic leukaemia and coexisting comorbidities
The current standard of care for patients with chronic lymphocytic leukaemia (CLL) and coexisting conditions…
EHA 2019: Venetoclax with bortezomib and dexamethasone shows good response but higher risk of treatment related death in relapsed / refractory multiple myleoma
Multiple myeloma is the second most common haematological cancer, and despite significant progress in the…
Study reports ibrutinib and venetoclax combo effective as front-line therapy for select chronic lymphocytic leukemia patients
Ibrutinib and venetoclax, two FDA-approved drugs for treating chronic lymphocytic leukemia (CLL), have been shown…
91 percent response rate for venetoclax against newly diagnosed AML in older adults
Clinical trial results published in the journal Nature Medicine show 91 percent response rate to the combination…